- Home
- YSG vs NEO Comparison
YSG vs NEO Comparison
Compare YSG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- NEO
- Stock Information
- Founded
- YSG 2016
- NEO 2001
- Country
- YSG China
- NEO United States
- Employees
- YSG N/A
- NEO N/A
- Industry
- YSG Package Goods/Cosmetics
- NEO Precision Instruments
- Sector
- YSG Consumer Discretionary
- NEO Health Care
- Exchange
- YSG Nasdaq
- NEO Nasdaq
- Market Cap
- YSG 889.0M
- NEO 1.0B
- IPO Year
- YSG 2020
- NEO 1999
- Fundamental
- Price
- YSG $10.01
- NEO $8.08
- Analyst Decision
- YSG
- NEO Buy
- Analyst Count
- YSG 0
- NEO 10
- Target Price
- YSG N/A
- NEO $12.56
- AVG Volume (30 Days)
- YSG 419.4K
- NEO 2.7M
- Earning Date
- YSG 08-21-2025
- NEO 11-04-2025
- Dividend Yield
- YSG N/A
- NEO N/A
- EPS Growth
- YSG N/A
- NEO N/A
- EPS
- YSG N/A
- NEO N/A
- Revenue
- YSG $522,879,337.00
- NEO $689,189,000.00
- Revenue This Year
- YSG $17.93
- NEO $10.40
- Revenue Next Year
- YSG $12.79
- NEO $10.11
- P/E Ratio
- YSG N/A
- NEO N/A
- Revenue Growth
- YSG 11.53
- NEO 9.70
- 52 Week Low
- YSG $3.01
- NEO $4.72
- 52 Week High
- YSG $11.57
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- YSG 54.06
- NEO 59.90
- Support Level
- YSG $10.01
- NEO $7.36
- Resistance Level
- YSG $10.70
- NEO $8.42
- Average True Range (ATR)
- YSG 0.56
- NEO 0.48
- MACD
- YSG 0.05
- NEO 0.02
- Stochastic Oscillator
- YSG 66.50
- NEO 63.02
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.